Invivyd, Inc. (IVVD)

Market Cap	71.98M
Revenue (ttm)	25.38M
Net Income (ttm)	-169.93M
Shares Out	119.96M
EPS (ttm)	-1.43
PE Ratio	n/a
Forward PE	5.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,811,366
Open	0.6014
Previous Close	0.6100
Day's Range	0.6000 - 0.6717
52-Week Range	0.3550 - 4.7400
Beta	0.09
Analysts	Strong Buy
Price Target	7.89 (+1,215.0%)
Earnings Date	Mar 20, 2025

About IVVD

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company’s pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Forecast

According to 4 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $7.89, which is an increase of 1,215.00% from the latest price.

Price Target

$7.89

(1,215.00% upside)

Analyst Consensus: Strong Buy